Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Gytz Ammitzbøll, Anne Troldborg, Susan Mikkelsen et al.|Lara D. Veeken|2022Cited by 16
COVID‐19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post‐Pandemic Concerns About the Impact of RituximabChristian Gytz Ammitzbøll, Anne Troldborg, Marianne Kragh Thomsen et al.|ACR Open Rheumatology|2024Cited by 5
Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patientsChristian Gytz Ammitzbøll, Anne Troldborg, Marianne Kragh Thomsen et al.|Clinical and Experimental Rheumatology|2023Cited by 3
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022–2025)Laura Nørgaard, Anne Troldborg, Mads Lamm Larsen et al.|Lupus|2026Cited by 0